Zai Lab Limited
HealthcareNASDAQ:ZLAB · NASDAQ Global Market
-$0.57 today
Vol 1.31M · Avg 0.84M
Management
Put operating results in leadership context
Review returns on capital, executive background, insider transactions, and growth quality to judge whether management is compounding value well.
Return Metrics
ROE, ROIC & ROA over time
ROE
-24.5%
avg -16.9%
ROIC
-22.7%
avg -50.2%
ROA
-15.0%
avg -42.0%
Analysis
ROA is currently the strongest return metric at -15.0% versus its period average of -42.0%. 0 of 3 return metrics are above their quality threshold, which helps indicate how efficiently the company turns capital and assets into profit.
Management
Key executives, compensation & ownership
| Name | Title | Compensation | Tenure | Age | Shares Owned | Ownership % |
|---|---|---|---|---|---|---|
Ying Du | Founder, Chairperson & Chief Executive Officer | $1.62M | — | 60 | $1.16M | 1.03% |
Joshua L. Smiley | President & Chief Operating Officer | $1.04M | — | 56 | $117,602.00 | 0.10% |
Rafael G. Amado | President and Head of Global Research & Development | $957,591.00 | — | 62 | $57,022.00 | 0.05% |
Frazor Titus Edmondson | Chief Legal Officer & Corporate Secretary | $842,364.00 | — | 60 | $19,849.00 | 0.02% |
Yajing Chen | Chief Financial Officer | $743,420.00 | — | 58 | $31,705.00 | 0.03% |
James Yan DABT | Chief Operating Officer of Global R&D | — | — | 62 | — | — |
Shan He | Senior Vice President & Chief Business Officer | — | — | — | — | — |
Tong Zhu | Chief Commercial Officer of Greater China | — | — | 48 | — | — |
Christine Chiou | Senior Vice President & Head of Investor Relations | — | — | — | — | — |
Insider Trading
SEC Form 4 transactions — last 12 months
Buys
2
$321,833.21
Sells
49
$19.68M
Net Sentiment
$19.36M
Net selling
Most Active
Du Ying
20 transactions
1–10 of 51
Analysis
Insiders reported 2 buys worth $321,833.21 and 49 sells worth $19.68M over the last 12 months. That adds up to net selling of $19.36M. Du Ying was the most active insider with 20 transactions.
Growth Analysis
Historical CAGR & forward analyst estimates
| Metric | 10yr | 5yr | 3yr | Fwd Est. |
|---|---|---|---|---|
| EPS | N/A | N/A | N/A | N/A2 analysts |
| Revenue | N/A | N/A | N/A | +53.7% (11yr)5 analysts |
| Net Income | N/A | N/A | N/A | N/A5 analysts |
| EBIT | N/A | N/A | N/A | N/A5 analysts |
Analysis
Forward estimates point to Revenue at +53.7% (11yr), giving you a quick read on expected growth from here.
Competitors
Peer companies in the same sector
Legend Biotech Corporation
NASDAQ:LEGN
$6.63B
Centessa Pharmaceuticals plc
NASDAQ:CNTA
$6.15B
Cidara Therapeutics, Inc.
CDTX
$5.61B
Apogee Therapeutics, Inc.
NASDAQ:APGE
$5.47B
Scholar Rock Holding Corporation
NASDAQ:SRRK
$5.29B
Xenon Pharmaceuticals Inc.
NASDAQ:XENE
$4.11B
Tarsus Pharmaceuticals, Inc.
NASDAQ:TARS
$2.67B
Disc Medicine, Inc.
NASDAQ:IRON
$2.60B
IDEAYA Biosciences, Inc.
NASDAQ:IDYA
$2.55B
Ascentage Pharma Group International
NASDAQ:AAPG
$409.04M
Who manages ZLAB?
Zai Lab Limited (ZLAB) lists 9 active executives. The top listed executive is James Yan DABT, Chief Operating Officer of Global R&D.
Are ZLAB insiders buying or selling?
Recent insider activity shows net selling of $22.69M.
Explore More
Continue the stock analysis
Jump to another research area for this company.